Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-10T08:44:57.016Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychiatric sequelae of MDMA (ecstasy) and related drugs

Published online by Cambridge University Press:  13 June 2014

Geraldine Cassidy  and
Clive G Ballard
Geraldine Cassidy
Affiliation:
St. Margaret's Hospital, Great Barr, Birmingham, B43 7EZ, England
Clive G Ballard
Affiliation:
University of Birmingham, Queen Elizabeth Psychiatric Hospital, Mindelsohn Way, Birmingham, B15 2QZ, England
Get access Rights & Permissions [Opens in a new window]

Abstract

Two cases of psychiatric disorder temporally related to the abuse of hallucinogenic amphetamines 3, 4 methylenedi-oxymethamphetamine (MDMA), methylenedioxyamphetamine (MDA) and methylenedioxyethylamphetamine (MDEA) are described, suggesting that a variety of psychiatric morbidity may be precipitated by abuse of these drugs, including paranoid psychosis, mixed affective psychosis and symptoms of obsessive compulsive disorder.

Keywords

Hallucinogenic amphetamines(MDMA, MDA, MDEA) Substance abuseDesigner drugsDrug induced psychosisAffective psychosisObsessive compulsive disorder
Type
Brief Reports
Information
Irish Journal of Psychological Medicine , Volume 11 , Issue 3 , September 1994 , pp. 132 - 133
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Morrison, V, Plant, M. Drug problems and pattern of service use amongst illicit drug users in Edinburgh. Br J Addict 1990; 85: 547–54.CrossRefGoogle ScholarPubMed
2.McGuire, P, Fahy, T. Chronic paranoid psychosis after mis-use of MDMA (“Ecstasy”). BMJ 1991; 302: 697.CrossRefGoogle Scholar
3.Schifano, F. Chronic atypical psychosis associated with MDMA (“Ecstasy”) abuse. Lancet 1991; 338: 1335.CrossRefGoogle ScholarPubMed
4.Benazzi, F, Mazzoli, M. Psychiatric illness associated with “Ecstasy”. Lancet 1991; 338: 1520.CrossRefGoogle ScholarPubMed
5.McGuire, P, Fahy, T. Flashback following MDMA. BMJ 1992; 160: 276.Google ScholarPubMed
6.Henry, JA, Jeffreys, KJ, Dawling, A. Toxicity and deaths from 3, 4 Methylenedioxymethamphetamine (“Ecstasy”). Lancet 1992; 340: 8816: 384–7.CrossRefGoogle ScholarPubMed
7.Leser, D. The Ecstasy Invasion. The Australian Magazine. The Australian 1989; 30–6.Google Scholar
8.Renfroe, CL. MDMA on the street, analysis anonymous. J Psychoactive Drugs 1986; 18: 363–9.CrossRefGoogle ScholarPubMed
9.Charney, DS, Goodman, WK, Price, LH, Woods, SW, Rasmussen, SA, Henninger, GR. Serotonin function in obsessive compulsive disorder. Arch Gen Psychiatry 1988; 45: 177–88.CrossRefGoogle ScholarPubMed
10.Ricaurte, GA, DeLanney, LE, Irwin, I, Langsten, JW. Toxic effects of MDMA on central serotonergic neurones in the primate; importance of route and frequency of drug administration. Brain Research 1988; 446: 165–8.CrossRefGoogle ScholarPubMed
11.Norvenius, G, Wildorlov, E, Lonerholm, G. Phenylpropylamine and mental disorder. Lancet 1979; ii: 1367–9.CrossRefGoogle Scholar
12.Thornicroft, G. Cannabis and Psychosis, is there epidemiological evidence for an association? Br J Psychiatry 1990; 157: 25–33.CrossRefGoogle ScholarPubMed
13.Tart, C. Marijuana intoxication; common experiences. Nature 1970; 226: 701–4.CrossRefGoogle ScholarPubMed